Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
Lysosomal Therapeutics, Inc. See All Filings	D	2019-11-07 17:26:03 UTC
Amount To Be Raised $3,000,000 Associated Brokers / Dealers N/A CIK Number 0001607854 Filed Document 0001607854-19-000001 Exclusions or Exemptions 506b Accepted Date 2019-11-07 17:26:03 UTC Type of Offering D Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Debt
Lysosomal Therapeutics, Inc. See All Filings	D/A	2017-01-18 11:55:49 UTC
Amount To Be Raised $26,124,936 Associated Brokers / Dealers N/A CIK Number 0001607854 Filed Document 0001607854-17-000001 Exclusions or Exemptions 506b Accepted Date 2017-01-18 11:55:49 UTC Type of Offering D/A Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
Lysosomal Therapeutics, Inc. See All Filings	D	2016-10-06 16:53:16 UTC
Amount To Be Raised $6,000,000 Associated Brokers / Dealers N/A CIK Number 0001607854 Filed Document 0001607854-16-000003 Exclusions or Exemptions 506b Accepted Date 2016-10-06 16:53:16 UTC Type of Offering D Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Debt
Lysosomal Therapeutics, Inc. See All Filings	D	2015-02-05 00:00:00 UTC
Amount To Be Raised $20,000,004 Associated Brokers / Dealers N/A CIK Number 0001607854 Filed Document 0001607854-15-000001 Exclusions or Exemptions 506b Accepted Date 2015-02-05 00:00:00 UTC Type of Offering D Industry Biotechnology Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
Lysosomal Therapeutics, Inc. See All Filings	D	2014-05-13 00:00:00 UTC
Amount To Be Raised $4,842,033 Associated Brokers / Dealers N/A CIK Number 0001607854 Filed Document 0001607854-14-000001 Exclusions or Exemptions 506b Accepted Date 2014-05-13 00:00:00 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity